A Multicenter Phase II Trial of Nimustine Hydrochloride Administered via Convection‐Enhanced Delivery in Children With DIPG
Ryuta Saito(Nagoya University), Teiji Tominaga(Tohoku University), Fumiaki Takahashi(Iwate Medical University), Kentaro Chiba(Tokyo Women's Medical University), Yoshiki Arakawa(Kyoto Prefectural University of Medicine), Masayuki Kanamori, Yukihiko Sonoda(Yamagata University), Yohei Mineharu(Kyoto University), Ichiyo Shibahara(Kitasato University), Manabu Kinoshita(Asahikawa Medical University), Yasuo Aihara(Kitasato University), Toshihiro Kumabe(Kitasato University), Kenichiro Matsuda(Yamagata University), Aya Sato(Tohoku University)
Cited by 4
Related Papers
Intertumoral Heterogeneity within Medulloblastoma Subgroups
|Cancer Cell|2017|1.3k
Subgroup-Specific Prognostic Implications of <i>TP53</i> Mutation in Medulloblastoma
|Journal of Clinical Oncology|2013|488
The Tohoku Medical Megabank Project: Design and Mission
|Journal of Epidemiology|2016|386
Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis
|The Lancet Oncology|2016|374
Characterization of two F4/80-positive Kupffer cell subsets by their function and phenotype in mice
|Journal of Hepatology|2010|284